Timothy A McKinsey


Affiliation: University of Colorado Denver
Country: USA


  1. Stratton M, Koch K, McKinsey T. p38?: A Profibrotic Signaling Nexus. Circulation. 2017;136:562-565 pubmed publisher
  2. Williams S, Golden Mason L, Ferguson B, Schuetze K, Cavasin M, Demos Davies K, et al. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol. 2014;67:112-25 pubmed publisher
  3. Demos Davies K, Ferguson B, Cavasin M, Mahaffey J, Williams S, Spiltoir J, et al. HDAC6 contributes to pathological responses of heart and skeletal muscle to chronic angiotensin-II signaling. Am J Physiol Heart Circ Physiol. 2014;307:H252-8 pubmed publisher
    ..These findings define novel roles for HDAC6 in striated muscle and suggest potential for HDAC6-selective inhibitors for the treatment of cardiac dysfunction and muscle wasting in patients with heart failure. ..
  4. Cavasin M, Demos Davies K, Schuetze K, Blakeslee W, Stratton M, Tuder R, et al. Reversal of severe angioproliferative pulmonary arterial hypertension and right ventricular hypertrophy by combined phosphodiesterase-5 and endothelin receptor inhibition. J Transl Med. 2014;12:314 pubmed publisher
    ..Combined therapy with two vasodilators that are approved for the treatment of human PAH provides unprecedented efficacy in the rat SU-Hx preclinical model of severe, angioproliferative PAH. ..
  5. Lemon D, Harrison B, Horn T, Stratton M, Ferguson B, Wempe M, et al. Promiscuous actions of small molecule inhibitors of the protein kinase D-class IIa HDAC axis in striated muscle. FEBS Lett. 2015;589:1080-8 pubmed publisher
    ..Based on these findings, caution is warranted when employing MC1568 and Gö-6976 as pharmacological tool compounds to assess functions of class IIa HDACs and PKD. ..
  6. Stratton M, McKinsey T. Epigenetic regulation of cardiac fibrosis. J Mol Cell Cardiol. 2016;92:206-13 pubmed publisher
  7. Reid B, Stratton M, Bowers S, Cavasin M, Demos Davies K, Susano I, et al. Discovery of novel small molecule inhibitors of cardiac hypertrophy using high throughput, high content imaging. J Mol Cell Cardiol. 2016;97:106-13 pubmed publisher
    ..Using annotated libraries of compounds with known selectivity profiles, this screening methodology also facilitates chemical biological dissection of signaling networks that control pathological growth of the heart. ..
  8. Jeong M, Lin Y, Wennersten S, Demos Davies K, Cavasin M, Mahaffey J, et al. Histone deacetylase activity governs diastolic dysfunction through a nongenomic mechanism. Sci Transl Med. 2018;10: pubmed publisher
    ..These data suggest that agents such as HDAC inhibitors, which potentiate cardiac myofibril relaxation, hold promise for the treatment of HFpEF in humans. ..
  9. Ferguson B, McKinsey T. Non-sirtuin histone deacetylases in the control of cardiac aging. J Mol Cell Cardiol. 2015;83:14-20 pubmed publisher
    ..g. HDAC2, HDAC3 and HDAC6). Potential for pharmacological HDAC inhibition as a means of treating age-related cardiac dysfunction is also discussed. This article is part of a Special Issue entitled: CV Aging. ..

More Information


  1. McKinsey T. Targeting inflammation in heart failure with histone deacetylase inhibitors. Mol Med. 2011;17:434-41 pubmed publisher
    ..This review highlights the roles of HDACs in the heart and the potential for using HDAC inhibitors as broad-based immunomodulators for the treatment of human heart failure. ..
  2. Blakeslee W, Wysoczynski C, Fritz K, Nyborg J, Churchill M, McKinsey T. Class I HDAC inhibition stimulates cardiac protein SUMOylation through a post-translational mechanism. Cell Signal. 2014;26:2912-20 pubmed publisher
  3. Stratton M, Lin C, Anand P, Tatman P, Ferguson B, Wickers S, et al. Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. Cell Rep. 2016;16:1366-1378 pubmed publisher
  4. Schuetze K, Stratton M, Blakeslee W, Wempe M, Wagner F, Holson E, et al. Overlapping and Divergent Actions of Structurally Distinct Histone Deacetylase Inhibitors in Cardiac Fibroblasts. J Pharmacol Exp Ther. 2017;361:140-150 pubmed publisher
    ..These findings illustrate the importance of employing multiple compounds when pharmacologically assessing HDAC function in a cellular context and during HDAC inhibitor drug development. ..
  5. Blakeslee W, Lin Y, Stratton M, Tatman P, Hu T, Ferguson B, et al. Class I HDACs control a JIP1-dependent pathway for kinesin-microtubule binding in cardiomyocytes. J Mol Cell Cardiol. 2017;112:74-82 pubmed publisher
    ..These findings define a novel role for class I HDACs in the control of the JIP1/kinesin axis in cardiomyocytes, and suggest that HDAC inhibitors could be used to alter microtubule transport in the heart. ..